Skeleton (bones) helps control sugar metabolism and weight, and it is found to be a major determinant of the development of type 2 diabetes, revealed by researchers at Columbia University Medical Center.
Today, researchers report for the first time that genetic variants in mitochondria?energy-producing structures harboring DNA that are inherited only from the mother?are directly linked to metabolic markers for type 2 diabetes. The study, which highlights the role of mitochondrial genome variation in the pathogenesis of common diseases, is published online in Genome Research (www.genome.org).
Menopausal women are at relatively high risk for memory loss, high blood pressure (hypertension) and diabetes. A decade ago, the standard treatment for these problems was long-term hormone replacement therapy (HRT). Since then, studies have shown that extensive use of HRT is associated with significant adverse effects.
Bones are typically thought of as calcified, inert structures, but researchers at Columbia University Medical Center have now identified a surprising and critically important novel function of the skeleton. They?ve shown for the first time that the skeleton is an endocrine organ that helps control our sugar metabolism and weight and, as such, is a major determinant of the development of type 2 diabetes.
A reanalysis of the data used in a previous analysis of the drug Rosiglitazone — marketed by GlaxoSmithKoine as Avandia — using different statistical models suggests that the earlier methodology may have resulted in inflated risk estimates.
Mothers of babies born with some structural birth defects?including missing limbs, malformed hearts and underdeveloped spinal cords?appear more likely to be obese prior to becoming pregnant than mothers whose children are born without such defects, according to a report in the August issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
Following a joint meeting of the US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development underscores its position that ACTOS (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.
Although more women are choosing to initiate breastfeeding, the percentage of mothers who breastfeed exclusively is far short of national objectives, according to a report in today’s Morbidity and Mortality Weekly Report (MMWR) issued by the Centers for Disease Control and Prevention (CDC).
The FDA Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted to keep the Glaxo’s diabetes medicine Avandia available to patients in the US. The FDA will review the panel’s recommendation before making a decision.
GlaxoSmithKline [NYSE: GSK] welcomed the nearly unanimous recommendation of an U.S. Food and Drug Administration?s (FDA) advisory committee to support Avandia?s (rosiglitazone maleate) continued availability to patients in the US.